MGA Report Comes in at Number One at The Center for Biosimilars
MGA Report Comes in at Number One at The Center for Biosimilars The Center for Biosimilars has announced that MGA’s recent report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was the top-read article on its...
MGA Report Featured by The Center for Biosimilars
MGA Report Featured by The Center for Biosimilars On Thursday, The Center for Biosimilars, a sister site of The American Journal of Managed Care, published an article discussing the differences between the patent systems in the United States and Europe when it comes...
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing Alex Brill and Christy Robinson | Washington, DC The white paper offers policy options to improve access to affordable biosimilar medicines. WASHINGTON,...
Shared Savings Models Could Yield Part B Savings
Shared Savings Models Could Yield Part B Savings Skylar Jeremias | The Center for Biosimilars “The establishment of a shared savings model has the potential to increase health care savings, biologic competition, and biosimilar utilization if implemented in...- Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug
- New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
- New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
- Narrow House GOP Victory Should Point Toward Policy Development Agenda
- Don’t Let Pandemic Fatigue Inhibit Pandemic Preparedness
- American Renewal: A Simpler, More Responsible, and Pro-Growth Tax System
- Macroeconomics of the Child Tax Credit
- 2022 Midterms: How a Democratic or GOP Congress May Impact Your Federal Taxes
- ‘The Price of Business’: Discussing State Taxation of Student Loan Forgiveness
- More Concerns with the Massachusetts Millionaire’s Tax
